New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2013
16:23 EDTACHNAchillion reports Q4 EPS (14c), consensus (20c)
Reports Q4 revenue $118,000, no consensus available.
News For ACHN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 22, 2014
06:40 EDTACHNAchillion to host conference call
Conference call to discuss positive results from two studies supporting a short duration, of its proprietary NS5A and nucleotide inhibitors, ACH-3102 and ACH-3422 will be held on December 22 at 8:30 am. Webcast Link
06:36 EDTACHNAchillion announces positive interim results for NS5A, ACH-3102
Achillion Pharmaceuticals announced positive interim results from two studies supporting a short duration, potentially best-in-disease regimen of its proprietary NS5A and nucleotide inhibitors, ACH-3102 and ACH-3422. Achillion announced 100% SVR4 results from the ongoing six-week trial. This study is an interferon-free, ribavirin-free, Phase 2 open-label, randomized study to evaluate the efficacy, safety, and tolerability of six weeks of 50 mg of ACH-3102 and 400 mg of sofosbuvir, a marketed nucleotide polymerase inhibitor, once daily, in treatment-na´ve genotype 1 HCV-infected patients. The primary objective of the study is determination of sustained viral response 12 weeks after completion of therapy. Achillion also announced today interim study results demonstrating that ACH-3422 achieved proof-of-concept in a Phase 1 trial for patients with treatment-na´ve genotype 1 HCV. In the 700 mg dose group, mean maximal reduction in HCV viral RNA load of 4.8 log10 IU/ml was observed within 14 days with 3 out of 6 patients achieving undetectable HCV RNA. The pharmacodynamic characteristics of ACH-3422 provided sustained antiviral activity resulting in an additional 1.4 log10 reduction in HCV RNA between day 7 and day 14 of dosing.
05:58 EDTACHNStocks with implied volatility above IV index mean; ACHN HLF
Stocks with implied volatility above IV index mean; Achillion (ACHN) 265, Herbalife (HLF) 76 according to iVolatility.
December 19, 2014
06:09 EDTACHNStocks with implied volatility above IV index mean; RSH ACHN
Stocks with implied volatility above IV index mean; RadioShack (RSH) 278, Achillion (ACHN) 269 according to iVolatility.
December 18, 2014
12:58 EDTACHNAchillion December weekly volatility elevated at 290
Achillion December call option implied volatility is at 205, December weekly at 290, January is at 263; compared to its 26-week average of 156 according to Track Data, suggesting large price movement.
06:00 EDTACHNStocks with implied volatility movement; DO ACHN
Stocks with implied volatility movement; Diamond Offshore (DO) 93, Achillion (ACHN) 285 according to iVolatility.
December 15, 2014
13:06 EDTACHNAchillion December volatility elevated at 285
Achillion December call option implied volatility is at 285, January is at 231; compared to its 26-week average of 153 according to Track Data, suggesting large price movement.
05:58 EDTACHNStocks with implied volatility above IV index mean; ACHN DG
Subscribe for More Information
December 8, 2014
11:49 EDTACHNAchillion December volatility elevated
Subscribe for More Information
08:32 EDTACHNTrout Group to hold events at ASH 2014
Subscribe for More Information
06:12 EDTACHNStocks with implied volatility above IV index mean; LULU ACHN
Stocks with implied volatility above IV index mean; lululemon (LULU) 53, Achillion (ACHN) 216 according to iVolatility.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use